Extended Data Fig. 1: Subgroup analyses for the primary end point. | Nature Medicine

Extended Data Fig. 1: Subgroup analyses for the primary end point.

From: Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial

Extended Data Fig. 1

Forest plot shows results of prespecified subgroup analyses for the primary efficacy end point lower-GI aGVHD-free survival by day+180 after allo-HSCT: sex; race; geographic region; primary disease; and GVHD prophylaxis, in addition to subgroup analyses reported in Fig. 2d. Analyses included all randomized patients who received ≥1 dose of study treatment and allo-HSCT; statistical tests were two-sided. Hazard ratios plotted with 95% confidence intervals were obtained via Cox proportional hazard model with treatment group stratified by randomization strata. ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; CML, chronic myeloid leukemia; CYS, cyclosporin; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; TAC, tacrolimus.

Back to article page